Page last updated: 2024-11-06

cabergoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cabergoline is a dopamine agonist that is used to treat hyperprolactinemia, a condition where the body produces too much prolactin. It is also used to treat Parkinson's disease and acromegaly. Cabergoline is a synthetic compound, meaning that it is not found naturally. It was first synthesized in the 1970s and is now marketed under the brand names Dostinex and Cabaser. Cabergoline works by stimulating dopamine receptors in the brain. This helps to reduce the production of prolactin. Cabergoline is also effective in treating Parkinson's disease by increasing dopamine levels in the brain. It is also used to treat acromegaly by reducing the production of growth hormone. Cabergoline is generally well-tolerated, but it can cause side effects such as nausea, vomiting, headache, and dizziness. It can also cause heart valve problems in some people. Cabergoline is a safe and effective treatment for hyperprolactinemia, Parkinson's disease, and acromegaly. It is important to talk to your doctor about the risks and benefits of cabergoline before taking it.'

Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54746
CHEMBL ID1201087
CHEBI ID3286
SCHEMBL ID42292
MeSH IDM0136060

Synonyms (104)

Synonym
(8beta)-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
BIDD:GT0775
chebi:3286 ,
cabergolinum
cabergolina
BRD-K86882815-001-01-6
gtpl37
caberlin
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2r,4r,7r)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
cabaseril
dostinex
cabaser
cg-101 ,
sogilen
(8beta)-n-[3-(dimethylamino)propyl]-n-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
brn 6020775
cabergolina [spanish]
cabergolinum [latin]
fce 21336
ergoline-8beta-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-
ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-
81409-90-7
cabergoline
C08187
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
DB00248
(8r)-6-allyl-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-n-[3-(dimethylamino)propyl]-n-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
cabaser (tn)
D00987
cabergoline (jan/usp/inn)
dostinex (tn)
HMS2090A09
CHEMBL1201087
velactis
unii-ll60k9j05t
ll60k9j05t ,
cabergoline [usan:usp:inn:ban]
cas-81409-90-7
tox21_112589
dtxcid502719
dtxsid6022719 ,
AKOS015961587
cabergoline [who-dd]
cabergoline [ema epar veterinary]
cabergoline [inn]
cabergoline [orange book]
cabergoline [jan]
cabergoline [mart.]
ergoline-8.beta.-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-
cabergoline [usp-rs]
1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
cabergoline [mi]
cabergoline [usan]
cabergoline [ep monograph]
cabergoline [vandf]
cabergoline [usp monograph]
S5842
bdbm50426497
HY-15296
SCHEMBL42292
NCGC00344544-01
tox21_112589_1
AB01275484-01
6-allyl-n-[3-(dimethylamino)propyl]-n-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide
KORNTPPJEAJQIU-KJXAQDMKSA-N
ethyl4-methyl-2-pyridin-3-yl-1,3-thiazole-5-carboxylate
(6ar,9r,10ar)-7-allyl-n-(3-(dimethylamino)propyl)-n-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
AC-26126
mfcd00867887
(6ar,9r,10ar)-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide
cabergoline, >=98% (hplc)
SR-05000001493-2
sr-05000001493
cabergoline, united states pharmacopeia (usp) reference standard
n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide
SR-05000001493-1
cabergoline, european pharmacopoeia (ep) reference standard
(9r,10ar)-7-allyl-n-(3-(dimethylamino)propyl)-n-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
F17353
Q423308
HMS3886H05
ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-
MS-28208
fce-21336fce-21336
cabergoline; 1-ethyl-3-[3-(dimethylamino)propyl]-3-[[(6ar,9r,10ar)-7-(prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]carbonyl]urea
cabergoline 1000 microg/ml in acetonitrile
EN300-19767804
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2r,4r,7r)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carbonyl]urea
cabergoline (usp-rs)
cabergoline (ema epar veterinary)
(8beta)-n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-ergoline-8-carboxamide
cabergoline (ep monograph)
g02cb03
cabergolinum (latin)
cabergoline (mart.)
n04bc06
(8r)-6-allyl-n-(3-(dimethylamino)propyl)-n-(ethylcarbamoyl)ergoline-8-carboxamide
1-((6-allylergoline-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
cabergoline (usan:usp:inn:ban)
cabergoline (usp monograph)
(8beta)-n-(3-(dimethylamino)propyl)-n-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide

Research Excerpts

Overview

Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT) Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas.

ExcerptReferenceRelevance
"Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT)."( Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors.
Amarù, J; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, LJ; Neggers, SJCMM; van der Lelij, AJ; van Koetsveld, PM, 2023
)
2.6
"Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. "( A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole.
Attanagoda, S; Miks, CD; Rodgers, R; Springer, C; Vivino, G,
)
1.83
"Cabergoline is an effective and well-tolerated strategy to prevent breast symptoms after second-trimester abortion or pregnancy loss."( Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.
Blumenthal, PD; Cahill, EP; Henkel, A; Johnson, SA; Reeves, MF; Shaw, KA, 2023
)
3.8
"Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. "( Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.
Lin, S; Wu, ZB; Zhang, A; Zhang, X, 2020
)
2.26
"Cabergoline is a potent dopamine receptor agonist of D2 receptors and has a direct inhibitory effect on pituitary PRL secretion."( A pilot study of cabergoline for the treatment of metastatic breast cancer.
Clevenger, CV; Costa, R; Flaum, L; Gradishar, WJ; Jain, S; Kaklamani, VG; Santa-Maria, CA; Scholtens, DM, 2017
)
1.52
"Cabergoline is a long-acting dopamine D2 agonist and ergot derivative that inhibits prolactin secretion and suppresses physiologic lactation when given as a single oral dose of 1 mg after delivery."( Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.
Boucoiran, I; Dodin, P; Elwood, C; Money, D; Tremblay-Racine, F; Tulloch, KJ, 2019
)
2.68
"Cabergoline is a safe and effective pharmacologic option for the prevention of physiological lactation and associated physical symptoms in non-breastfeeding women. "( Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.
Boucoiran, I; Dodin, P; Elwood, C; Money, D; Tremblay-Racine, F; Tulloch, KJ, 2019
)
3.4
"Cabergoline is a long-acting dopamine receptor agonist used for treatment of patients with uncured Cushing's disease (CD) and, as a first-line treatment, was used in only limited numbers of patients. "( Remission with cabergoline in adolescent boys with Cushing's disease.
Baltacıoğlu, F; Cebeci, AN; Dursun, F; Güven, A; Kırmızıbekmez, H, 2013
)
2.19
"Cabergoline is an ergot-derived dopamine D2 receptor agonist which may be effective for the medical management of acromegaly. "( Cabergoline treatment in acromegaly: pros.
Bernabeu, I; Marazuela, M; Ramos-Leví, A; Sampedro-Núñez, M, 2014
)
3.29
"Cabergoline is a recommended first-line dopamine agonist for prolactinoma treatment, which is withdrawable for some cases. "( Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu, J; Yang, H; Zhang, W; Zheng, X, 2015
)
2.09
"Cabergoline is an ergot derivative with high affinity for the D2 dopamine receptors whose dopaminergic effects cause inhibition of prolactin (PRL) secretion; thus, it could be considered a molecule that acts as a potential dry-off facilitator. "( Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior.
Aris, A; Bach, A; De-Prado, A, 2015
)
2.13
"Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). "( Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.
Akha, O; Ala, S; Bahar, A; Daneshpour, E; Kashi, Z, 2016
)
2.27
"Cabergoline is a high selective agonist of dopamine D2 receptors (D2R). "( [An effect of cabergoline on alcohol consumption and DRD2 expression in the brain of rats with chronic alcohol intoxication].
Anokhin, PK; Anokhina, IP; Proskuryakova, TV; Shamakina, IY; Shokhonova, VA; Tapabarko, IE; Ulyanova, EV,
)
1.93
"Cabergoline is a dopamine agonist that may be used as primary or adjunctive therapy for acromegaly. "( Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Drake, WM; Metcalfe, KA; Moyes, VJ, 2008
)
2.13
"Cabergoline is a synthetic dopamine agonist used to treat Parkinson disease. "( [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
Genís-Batlle, D; Haro-Estarriol, M; Obrador-Lagares, A; Rodríguez-Jerez, F; Sabater-Talaverano, G; Sendra-Salillas, S, 2009
)
2.01
"Cabergoline is an ergotamine derivative that increases the expression of glial cell line-derived neurotrophic factor (GDNF) in vitro. "( Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.
Ahmadiantehrani, S; Bartlett, SE; Carnicella, S; He, DY; Janak, PH; Nielsen, CK; Ron, D, 2009
)
3.24
"Cabergoline is an ergot derivative with a high affinity to dopamine D(2)-like receptors; however, there have been few preclinical studies on its antidepressant-like effects."( Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.
Chiba, S; Kunugi, H; Ninomiya, M; Numakawa, T; Yoon, HS, 2010
)
2.52
"Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. "( Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Baynes, KC; Cabrita, IZ; Dhillo, WS; Eliahoo, J; Grogono, J; Hensman, D; Martin, NM; Meeran, K; Nihoyannopoulos, P; Robinson, S; Tan, T, 2010
)
2.04
"Cabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. "( Cabergoline monotherapy in the long-term treatment of Cushing's disease.
Beauregard, H; Bruno, OD; Danilowicz, K; Godbout, A; Lacroix, A; Manavela, M, 2010
)
3.25
"Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. "( A practical synthesis of cabergoline.
Anderson, AM; Ashford, SW; Henegar, KE; Wuts, PG, 2002
)
2.06
"Cabergoline is an ergot-derived dopamine agonist used in the treatment of Parkinson's disease (PD). "( Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD, 2002
)
2.05
"Cabergoline is a well tolerated drug."( [Cabergoline in the treatment of Parkinson's disease].
Pastor, P; Tolosa, E, 2003
)
1.95
"Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for D(2) receptors indicated for use in both early and advanced Parkinson's disease and in hyperprolactinaemic disorders. "( Clinical pharmacokinetics of cabergoline.
Bonuccelli, U; Del Dotto, P, 2003
)
2.05
"Cabergoline is an ergoline derivative with a very long half-life that allows once-daily administration and the potential for more continuous stimulation of dopaminergic receptors than is possible with other dopamine receptor agonists (DAs). "( The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL, 2004
)
2.03
"Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for dopamine D2 receptors and a long elimination half-life. "( Cabergoline : a review of its use in the treatment of Parkinson's disease.
Curran, MP; Perry, CM, 2004
)
3.21
"Cabergoline is an efficacious and well-tolerated option for the treatment of restless legs symptoms during the night and the day."( Effective cabergoline treatment in idiopathic restless legs syndrome.
Benes, H; Emser, W; Holinka, B; Hornyak, M; Kohnen, R; Leroux, M; Oertel, WH; Peglau, I; Stiasny-Kolster, K; Wessel, K, 2004
)
2.17
"Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors. "( [Use of cabergoline in persisting Cushing's disease].
Dubois-Ginouves, S; Illouz, F; Laboureau, S; Rodien, P; Rohmer, V, 2006
)
2.21
"Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. "( Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
Abs, R; Bárcena, DG; Chanson, P; Colao, A; Kleinberg, DL; Paulus, W, 2008
)
2.08
"Cabergoline is an ergotic dopamine agonist with D2 receptor activity and a very long half-life. "( Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro, G,
)
1.85
"Cabergoline (CG) is a dopamine agonist that inhibits the secretion of prolactin (PRL) and growth hormone. "( In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T, 1995
)
2.07
"Cabergoline (CG) is a dopamine agonist that inhibits secretion of prolactin (PRL) and growth hormone. "( Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.
Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T, 1995
)
2.14
"Cabergoline is a synthetic ergoline which shows high specificity and affinity for the dopamine D2 receptor. "( Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Bryson, HM; Fitton, A; Rains, CP, 1995
)
3.18
"Cabergoline is a new, long-acting D2 agonist, highly effective in suppressing prolactin and restoring gonadal function in hyperprolactinaemic amenorrhoea. "( [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G, 1995
)
1.99
"Cabergoline is a new prolactin-lowering drug, more effective and better tolerated with fewer gastrointestinal symptoms than the reference compound, bromocriptine."( [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G, 1995
)
1.99
"Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. "( A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Ferrari, CI; Ismail, I; Piscitelli, G; Polli, A; Scanlon, MF; Webster, J, 1994
)
2.08
"Cabergoline appears to be a promising agent in the treatment of Parkinson's disease."( Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
Brewer, MA; Hutton, JT; Morris, JL, 1993
)
1.24
"Cabergoline is a new dopamine agonist with a long half-life and can be given in a single daily dose."( Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
Inzelberg, R; Korczyn, AD; Nisipeanu, P; Rabey, MJ, 1995
)
1.28
"Cabergoline is a new long-acting crgoline derivative used to treat hyperprolactinaemia. "( Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange, E; Donckier, J; Maiter, D, 1996
)
2.02
"Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. "( Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH, 1996
)
2
"Cabergoline is a long-acting D2 dopamine (DA) agonist. "( Cabergoline in Parkinson's disease complicated by motor fluctuations.
Caraceni, T; Fetoni, V; Geminiani, G; Genitrini, S; Giovannini, P; Tamma, F, 1996
)
3.18
"Cabergoline, which is a long-acting dopamine D2-like receptor agonist, has been tried recently with good results as an adjunct in patients already on levodopa-therapy."( Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.
Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R, 1996
)
2.46
"Cabergoline is a long-acting dopamine agonist specific for the D2 receptor that is more effective and better tolerated than bromocriptine in women with microadenomas or idiopathic hyperprolactinemia."( Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller, BM; Cannistraro, KB; Davis, KR; Klibanski, A; Molitch, ME; Schoenfelder, JR; Simons, JA; Vance, ML, 1996
)
1.24
"Cabergoline is a potent D2 receptor agonist with a half-life of 65 hours that may provide continuous dopaminergic stimulation administered once daily. "( Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK, 1997
)
3.18
"Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. "( Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J, 1998
)
3.19
"Cabergoline (CAB) is a long-acting dopamine agonist. "( [Treatment of hyperprolactinemic amenorrhea with cabergoline].
Chervin, A; Fideleff, HL; Gurucharri, C; Holland, ME; Sinai, I, 1997
)
1.99
"Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. "( Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J, 1999
)
3.19
"Cabergoline (CAB) is a potent dopamine agonist and an inhibitor of prolactin (PRL). "( Bait-delivered cabergoline for the reproductive control of the red fox (Vulpes vulpes): estimating mammalian non-target risk in south-eastern Australia.
Marks, CA, 2001
)
2.11
"Cabergoline is a new ergot derivative with long-lasting PRL lowering effect. "( LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinaemic patients.
Carraro, A; Durante, R; Giusti, M; Porcella, E,
)
1.8
"Cabergoline is a potent dopaminergic agent that interacts with agonists and antagonists of dopamine receptors in vitro. "( In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.
Barone, D; Benedetti, MS; Dostert, P; Efthymiopoulos, C; Peretti, G; Roncucci, R, 1990
)
2.03
"Cabergoline (CAB) is a new oral dopaminergic compound showing a very long-lasting PRL-lowering activity and reported to be well tolerated. "( Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D, 1989
)
1.96
"Cabergoline (CAB) is a new ergolinic derivative with a long-acting dopaminergic activity."( Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
Durante, R; Giordano, G; Giusti, M; Lomeo, A; Mazzocchi, G; Sghedoni, D; Torre, R, 1989
)
1.33

Effects

Cabergoline has minimal clinically-relevant hemodynamic effects and was well tolerated among normotensive postpartum women. Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease.

ExcerptReferenceRelevance
"Cabergoline has minimal clinically-relevant hemodynamic effects and was well tolerated among normotensive postpartum women."( Cabergoline for postpartum lactation suppression: Effect on blood pressure and pulse.
Baechler, M; Hitti, J; Humphrey, S; Schiff, M, 2022
)
3.61
"cabergoline 0.5 mg/week) have been the most consistently identified predictors of success."( Dopamine agonists in prolactinomas: when to withdraw?
Belo, S; Carvalho, D; Souteiro, P, 2020
)
1.28
"Cabergoline has been demonstrated to be effective and should be considered as a first-line treatment for hyperprolactinemia. "( Treatment of hyperprolactinemia: A single-institute experience.
Chen, TY; Cheng, WY; Chien, Y; Huang, YF; Lai, CM; Lee, CH; Shen, CC; Yang, MY; Yang, YP, 2021
)
2.06
"Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated."( Cabergoline in severe ectopic or occult Cushing's syndrome.
Borson-Chazot, F; Ilie, MD; Raverot, G; Raverot, V; Tronc, F; Vasiljevic, A, 2019
)
3.4
"Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. "( Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma, RS; Colao, A; Ferreri, L; Gasperi, M; Grasso, LF; Iacuaniello, D; Perone, Y; Pivonello, R; Simeoli, C, 2013
)
2.11
"Cabergoline has also been used as monotherapy in PD and has been shown to be as effective as other dopamine agonists in improving motor function and to be superior to levodopa in reducing dyskinesias over a five-year period."( Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Appiah-Kubf, LS; Chaudhuri, KR; Porter, MC,
)
1.09
"Cabergoline has the longest half-life of the dopamine agonists currently available and is effective when given once-daily."( Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD, 2002
)
1.33
"Cabergoline has been shown to be more effective and better tolerated than bromocriptine."( Hyperprolactinemia: etiology, diagnosis, and management.
Mah, PM; Webster, J, 2002
)
1.04
"Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. "( Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Horikawa, F; Kawabata, Y; Miki, N; Miyake, H; Ono, M; Ueno, Y, 2008
)
2.1
"Cabergoline has been compared with placebo in two phase II (6 - 12 weeks) and one phase III randomised controlled trials (24 weeks). "( Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke, CE; Deane, KH, 2001
)
3.2
"Cabergoline has been compared with bromocriptine in five randomised, double-blind, parallel group studies including 1071 patients. "( Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke, CE; Deane, KD, 2001
)
3.2

Actions

Cabergoline can suppress GH secretion in approximately 40% of acromegalic patients. Cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.

ExcerptReferenceRelevance
"Cabergoline at lower doses than those employed in Parkinson's disease is widely used in patients with prolactinomas, because of its high efficacy and tolerability; however, its safety with regard to cardiac valve disease is unknown."( Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
Aris-Jilwan, N; Beauregard, H; Delorme, S; Garfield, N; Houde, G; Kahtani, N; Rivera, J; Santagata, P; Serri, K; Serri, O; Vallette, S, 2009
)
1.48
"Cabergoline can suppress GH secretion in approximately 40% of acromegalic patients."( The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Bidlingmaier, M; Gutt, B; Roemmler, J; Schneider, HJ; Schopohl, J; Sievers, C; Steffin, B, 2010
)
1.34
"Cabergoline was added because of the presence of persistent mildly increased IGF-I."( Pegvisomant and cabergoline combination therapy in acromegaly.
Alvarez-Escolá, C; Bernabeu, I; Cabezas-Agrícola, JM; Casanueva, FF; Lucas, T; Marazuela, M; Paniagua, AE; Pavón, I, 2013
)
1.46
"Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine."( Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Demedts, M; Dom, R; Frans, E, 1992
)
0.95

Treatment

Cabergoline was given as treatment, starting with 0.5 mg/day and tapered necessarily. The pituitary adenoma showed a significant shrinkage on MRI and urinary cortisol excretion remained within the normal range during 7 years. Cabergoline-treated patients experienced a significantly higher frequency of peripheral oedema.

ExcerptReferenceRelevance
"Cabergoline co-treatment with L-dopa reduced LID, striatal preprodynorphin mRNA expression, and hypertrophy of the entopeduncular nucleus, indicating that cabergoline has an anti-LID effect independent of the L-dopa-sparing effect."( Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K, 2022
)
2.89
"Cabergoline treatment achieved a 50% reduction in adenoma size in the first year of treatment without high doses."( Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Berberoğlu, M; Bilici, E; Ceran, A; Kontbay, T; Özsu, E; Şıklar, Z; Uyanık, R, 2022
)
1.44
"Cabergoline-treated cows significantly reduced the risk of new IMI by major pathogens across the dry period and postcalving by 21% when compared with placebo cows (20.5 vs."( Efficacy of cabergoline in a double-blind randomized clinical trial on milk leakage reduction at drying-off and new intramammary infections across the dry period and postcalving.
Bertet, J; de Prado-Taranilla, AI; Deflandre, A; Hop, GE; Isaka, N; Ocak, M; Schukken, YH; Supré, K; Velthuis, A, 2019
)
1.61
"Cabergoline is the treatment of choice for prolactinomas. "( Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Abucham, J; Correa-Silva, SR; Portari, LHC, 2022
)
2.44
"Cabergoline treatment more than doubled decidual biomarker expression, whereas risperidone, a dopamine receptor antagonist, inhibited ESC differentiation by >50%."( Cabergoline Stimulates Human Endometrial Stromal Cell Decidualization and Reverses Effects of Interleukin-1β In Vitro.
Berga, SL; Kohout, TA; Meng, Q; Taylor, RN; van Duin, M; Xia, M; Yu, J, 2021
)
2.79
"Cabergoline as first-line treatment (n = 11, median follow-up of 37 months, range 12-89 months) induced normoprolactinemia (n = 8), reduced the mean tumour volume by 80%, and ameliorated headaches (p = 0.016) and pubertal delay (p = 0.031), whereas intermittent moderate side effects occurred in 55%."( Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature.
Bettendorf, M; Breil, T; Choukair, D; Inta, I; Jesser, J; Klose, D; Lorz, C; Mittnacht, J; Schulze, E, 2018
)
1.2
"Cabergoline treatment reduced the severity of both obstructive and central sleep apneas in this patient."( Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas.
Arslan, H; Binar, M; Haymana, C; Karakoc, O,
)
2.3
"Cabergoline treatment (at first 1.5 mg/week, and then increased to 3.5 mg/week after 3 months) achieved prolactin suppression; however, magnetic resonance revealed a stable mass."( Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Albiger, N; Ceccato, F; Lombardi, G; Mazzai, L; Pambuku, A; Rolma, G; Scaroni, C; Zagonel, V, 2019
)
1.49
"Cabergoline is the treatment of choice for prolactin (PRL)-producing pituitary adenomas, because of its efficacy in normalizing PRL levels, and inducing tumor shrinkage. "( Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Fujii, S; Kambe, A; Kurosaki, M; Ogawa, T; Watanabe, T, 2015
)
2.12
"Cabergoline treatment was started with dose of 1.5 mg/week."( Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
Evran, S; Hanimoglu, H; Ilhan, MM; Kaynar, MY; Tasan, E; Turgut, S, 2015
)
1.41
"Cabergoline treatment decreased the plasma PRL concentrations during the first week of dry-off, compared with the control treatment."( Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off.
Boutinaud, M; De Prado Taranilla, AI; Deflandre, A; Dessauge, F; Gandemer, E; Isaka, N; Lamberton, P; Lollivier, V; Sordillo, LM, 2016
)
2.6
"Cabergoline treatment induced a significant reduction of the E-MSC angiogenic potential (P < 0.05 versus control)."( Angiogenic properties of endometrial mesenchymal stromal cells in endothelial co-culture: an in vitro model of endometriosis.
Benedetto, C; Brossa, A; Bussolati, B; Canosa, S; Leoncini, S; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A, 2017
)
1.18
"Cabergoline treatment decreased alcohol-drinking and -seeking behaviors including relapse, and its action to reduce alcohol consumption was localized to the VTA."( Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.
Ahmadiantehrani, S; Bartlett, SE; Carnicella, S; He, DY; Janak, PH; Nielsen, CK; Ron, D, 2009
)
2.52
"Cabergoline treatment for more than 12 months caused a greater reduction in tumor size compared to the treatment for less than 12 months (97+/-1% vs."( Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho, EH; Cho, YH; Chung, JY; Kim, CJ; Kim, JH; Kim, MS; Koh, EH; Lee, SA, 2009
)
1.38
"Cabergoline treatment at the time of conception appears to be safe for both the pregnancy and the neonate, although more data are still needed on a larger number of pregnancies."( Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Bernard, P; Hubinont, C; Lebbe, M; Maiter, D, 2010
)
2.05
"Cabergoline treatment."( Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline.
Balasch, J; Castelo-Branco, C; Martinez, MJ, 2011
)
2.03
"With cabergoline treatment the patient was asymptomatic, the pituitary adenoma showed a significant shrinkage on MRI and urinary cortisol excretion remained within the normal range during 7 years."( Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.
Bruno, OD; Danilowicz, K; Manavela, MP, 2012
)
1.06
"Cabergoline was given as treatment, starting with 0.5 mg/day and tapered necessarily."( Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Cakir, B; Caner, S; Ersoy, R; Inancli, SS; Tam, AA; Usluogullari, A; Ustu, Y, 2013
)
1.51
"Mean cabergoline treatment durations beginning in early, mid-, and late anestrus were 27.4+/-3.7, 17.6+/-3.8, and 5+/-3 days (LSM+/-SEM), respectively."( Shortening of interestrous intervals with cabergoline in bitches: a clinical trial.
Castex, G; Corrada, Y; Dela sota, L; Gobello, C,
)
0.85
"Cabergoline-treated patients also experienced a significantly higher frequency of peripheral oedema (16.1% vs 3.4%, respectively; p < 0.0001)."( The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL, 2004
)
1.31
"Cabergoline-treated participants demonstrated a significant improvement over placebo from baseline to week 8 when measured using the Addiction Severity Index (ASI) employment subscale (overall change = - 0.09, SD = 0.10, t = 2.36, P < 0.05)."( Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
Ling, W; Majewska, MD; Montgomery, MA; Rawson, RA; Reiber, C; Shoptaw, S; Watson, DW, 2005
)
1.32
"Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma."( PRL secreting adenomas in male patients.
Ciccarelli, A; Colao, A; De Rosa, M; Guerra, E; Lombardi, G; Milone, F; Zarrilli, S, 2005
)
1.05
"Cabergoline treatment was initiated and was well tolerated."( A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy.
Elder, DA; Eyal, O; Naffaa, LN, 2005
)
1.05
"Cabergoline treatment reverses alterations in semen."( The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
Ciccarelli, A; Colao, A; De Rosa, M; Di Sarno, A; Gaccione, M; Guerra, E; Lombardi, G; Zarrilli, S, 2006
)
1.38
"Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases."( Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.
Loew, T; Moleda, D; Nickel, M; Pedrosa Gil, F; Rother, W,
)
2.3
"Cabergoline treatment also induces tumor shrinkage in the majority of patients with macroprolactinomas."( Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A, 2006
)
1.42
"Cabergoline treatment and transsphenoidal surgery."( Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH, 2006
)
2.01
"Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18-1718 mg."( Cabergoline and the risk of valvular lesions in endocrine disease.
Beckers, A; Betea, D; Burlacu, MC; Daly, AF; Lancellotti, P; Livadariu, E; Markov, M; Pierard, L, 2008
)
2.51
"On cabergoline treatment normal serum PRL levels were achieved within 3 months along with a marked shrinkage of the adenoma but growth rate did not increase nor did puberty start."( Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Beck-Peccoz, P; Borretta, G; Cesario, F; Meineri, I; Muratori, M; Pizzocaro, A,
)
1.06
"Cabergoline treatment alone increased (P < 0.001) mean plasma LH concentrations at day 26 but not at days 12 and 16 of lactation."( Treatment of lactating sows with the dopamine agonist Cabergoline: effects on LH and prolactin secretion and responses to challenges with naloxone and morphine.
De Rensis, F; Foxcroft, GR; Quintavalla, F, 1998
)
1.27
"Cabergoline (CAB) treatment is an effective, safe and well tolerated approach for hyperprolactinemia. "( Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Almoto, B; Cannavò, S; Curtò, L; Squadrito, S; Trimarchi, F; Vieni, A, 1999
)
3.19
"Cabergoline treatment was started in either early anestrus (Days 93 to 108), mid-anestrus (Days 123 to 156), or late anestrus (Days 161 to 192) at doses of 5 ug/kg/d, per os, and was continued until the confirmation of induced proestrus or for 40 d."( Effect of stage of anestrus on the induction of estrus by the dopamine agonist cabergoline in dogs.
Concannon, PW; Onclin, K; Silva, LD; Verstegen, JP, 1999
)
1.25
"2. Cabergoline treatment decreased by half striatal D2 receptor binding density measured by [3H]spiperone autoradiography versus untreated MPTP monkeys."( Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys.
Bédard, PJ; Di Paolo, T; Falardeau, P; Goulet, M; Grondin, R; Maltais, S; Morissette, M, 2000
)
1.09
"In cabergoline pretreated rats, the number of rotations was significantly lower than that of saline-pretreated animals."( Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Abe, K; Kashihara, K; Manabe, Y; Murakami, T, 2002
)
0.83
"Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug."( [Hyperprolactinemia in the postmenopause: versions and contraversions].
Leshchenko, OY, 2021
)
0.96
"Treatment with cabergoline at the dose of 0.25 mg twice weekly was started and increased according to prolactin levels and continued for 6 months."( Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
Akbari, H; Golgiri, F; Kabootari, M; Khajavi, A; Mosalamiaghili, S; Shirmohammadli, H, 2023
)
1.25
"Treatment with cabergoline is well tolerated and effective in reducing clinical symptoms and prolactin concentrations was well as inducing tumour shrinkage."( Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature.
Bettendorf, M; Breil, T; Choukair, D; Inta, I; Jesser, J; Klose, D; Lorz, C; Mittnacht, J; Schulze, E, 2018
)
0.82
"Treatment with cabergoline led to a 99.8% reduction in serum prolactin levels and significant tumor shrinkage."( Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Bettencourt-Silva, R; Carvalho, D; Pereira, J; Queirós, J, 2018
)
0.82
"Treatment with cabergoline resulted in a marked reduction in prolactin concentration in all nine patients."( Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta, CM; Krebs, A; Schwab, KO; van der Werf-Grohmann, N; Wurm, M, 2019
)
1.08
"When treated with cabergoline, testosterone levels in these men can increase higher within the normal range together with clinical improvement."( Male prolactinomas presenting with normal testosterone levels.
Benbassat, C; Shimon, I, 2014
)
0.73
"Treatment with cabergoline was initiated resulting in improvement in visual fields, tumor shrinkage and prolactin level decrease."( Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Fountoulakis, S; Liberopoulos, K; Malliopoulos, D; Markou, A; Papanastasiou, L; Pappa, T; Piaditis, G,
)
0.73
"Treatment with cabergoline was initiated, but the tumor continued to grow during a 6-month period."( Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma.
Corn, HJ; Couldwell, WT; Eli, IM; Palmer, CA; Raheja, A; Simmons, DL, 2016
)
1.03
"Treatment with cabergoline resulted in complete resolution of both types of headache and the menstrual cycle and prolactin levels returned to normal."( How to investigate and treat: headache and hyperprolactinemia.
Bussone, G; Moschiano, F; Usai, S, 2012
)
0.72
"Treatment with cabergoline was started with normalization of prolactin levels; the following MRI, performed in 2005 and 2008, showed shrinkage of the pituitary lesion."( Double pituitary adenomas.
Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D, 2013
)
0.73
"Treatment with cabergoline (Sogilen) had been started 4 months earlier."( [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
Gayete, A; Grau, S; Orozco-Levi, M; Ramírez-Sarmiento, A; Villavicencio, C, 2007
)
0.93
"Treatment with cabergoline suppressed plasma IGF-I below 300 micrograms/L in 39% of cases and between 300-450 micrograms/L in another 28%."( Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J, 1998
)
2.08
"Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas."( Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J, 1999
)
2.09
"Treatment with cabergoline (CAB) resulted in rapid normalization of serum PRL (6 weeks after initiation of treatment) and reduction of tumor size."( Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
Kaltsas, T; Krassas, GE; Pontikides, N, 1999
)
0.86
"Treatment with cabergoline was associated with a significant reduction in prolactin concentration (74341 +/- 31939 mU/l vs. "( Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
Davies, JS; George, LD; Nicolau, N; Scanlon, MF, 2000
)
0.92
"Treatment with cabergoline showed higher efficacy and greater safety than other parkinsonian drugs."( Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
Baas, HK; Schueler, P, 2001
)
1.03

Toxicity

Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events. The Naranjo scale pointed to a probable relationship between cabergoline and these adverse effects.

ExcerptReferenceRelevance
" In male rats no adverse effects were seen on male reproductive performance or on the offspring at doses up to 320 micrograms/kg/d given for 10 weeks prior to mating with untreated females."( Reproductive toxicity of cabergoline in mice, rats, and rabbits.
Beltrame, D; Longo, M; Mazué, G,
)
0.43
"Drug safety was assessed by adverse events; efficacy was evaluated with the RLS-6 and the International RLS Rating Scales."( Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
Benes, H; Heinrich, CR; Kohnen, R; Ueberall, MA, 2004
)
0.6
"In 48% of the study participants, investigators reported adverse events suspected to be drug related."( Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
Benes, H; Heinrich, CR; Kohnen, R; Ueberall, MA, 2004
)
0.6
"Long-term therapy with cabergoline is a safe and well-tolerated treatment option for the great majority of patients with idiopathic RLS."( Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
Benes, H; Heinrich, CR; Kohnen, R; Ueberall, MA, 2004
)
0.92
" Twenty-four drug-related adverse events were recorded of which four were regarded as serious."( Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G, 2006
)
0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The Naranjo scale pointed to a probable relationship between cabergoline and these adverse effects."( [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
Gayete, A; Grau, S; Orozco-Levi, M; Ramírez-Sarmiento, A; Villavicencio, C, 2007
)
0.84
" Adverse events, all of which were mild, occurred in 29."( Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
Abe, T; Hamada, T; Kashihara, K; Kawamura, J; Kowa, H; Nogawa, S; Ogino, Y; Tachibana, H; Takahashi, H,
)
0.13
"This study evaluated the prevalence and risk of fibrotic adverse reactions during cabergoline therapy in hyperprolactinemic and acromegalic patients."( Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM, 2010
)
0.81
"Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events."( Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM, 2010
)
2.03
"Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients."( Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
Cobo, J; Coronas, R; Giménez-Palop, O; Márquez, M; Ortega, E, 2012
)
1.08
"DA are safe and well tolerated, and the main safety concerns are related to the potential risk of clinically relevant valvulopathy following treatment with CAB, rarely occurring in patients with prolactinomas."( The safety of treatments for prolactinomas.
Auriemma, RS; Colao, A; Grasso, LF; Pivonello, R, 2016
)
0.43
" We concluded that early administration of cabergoline is a safe and potentially more effective approach for prophylaxis against OHSS in high risk cases."( Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
El Maghraby, HA; El-Gezary, D; Gaafar, S, 2019
)
1.13
" All treatments were well tolerated with a slight excess of adverse events in the combination arms."( Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W, 2019
)
0.72
"This study sought to perform a systematic review of adverse events reported with the use of cabergoline for postpartum lactation inhibition or suppression in women aged 15 to 50."( Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review.
Harris, K; Horn, D; MacGilivray, J; Murphy, KE; Yudin, MH, 2020
)
1.18
" The incidence of adverse drug reactions was 35."( Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H, 2020
)
0.56
" The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%-16%."( The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y, 2023
)
0.91
"8%) were the most frequent adverse events."( Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Bex, M; Biller, BMK; Boguszewski, CL; Chattopadhyay, A; Feelders, RA; Fleseriu, M; González-Devia, D; Kadioglu, P; Maamari, R; Patino, H; Pedroncelli, AM; Pivonello, R; Yavuz, DG, 2023
)
1.13

Pharmacokinetics

Cabergoline has a very long mean plasma elimination half-life of 65 to 110 hours. absorption and excretion are unaffected by food, age or renal or hepatic disease. When given concomitantly, cabergoline does not influence levodopa pharmacokinetics.

ExcerptReferenceRelevance
" The analysis of variance performed on the pharmacodynamic effects of the two cabergoline formulations indicated that the percent decreases of plasma prolactin levels were not significantly different for tablets and solution."( Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
Bizollon, CA; Edwards, DM; Persiani, S; Pianezzola, E; Piscitelli, G; Poggesi, I; Sassolas, G; Strolin Benedetti, M, 1994
)
0.77
" This study aimed at examining whether the plasma pharmacokinetic parameters of cabergoline and selegiline are modified when given in combination."( Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D, 1995
)
0.75
" In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12."( The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.
Holt, B; Pacciarini, MA; Persiani, S; Rocchetti, M; Strolin-Benedetti, M; Toon, S, 1996
)
0.92
"Previous investigations on the mutual pharmacokinetic influence of L-dopa and dopamine agonists in Parkinson's disease (PD) have shown controversial results."( Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M, 1997
)
0.55
" It has an appropriate receptor affinity profile, with potent and long-lasting dopaminergic stimulatory effects in 6-hydroxydopamine-lesioned rats and in MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine)-lesioned primates; it has a consistent pharmacokinetic profile, with a very long mean plasma elimination half-life of 65 to 110 hours, and its absorption and excretion are unaffected by food, age or renal or hepatic disease; moreover, when given concomitantly, cabergoline does not influence levodopa pharmacokinetics."( Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello, RG, 1998
)
0.72
" The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours."( Clinical pharmacokinetics of cabergoline.
Bonuccelli, U; Del Dotto, P, 2003
)
0.9
" In healthy male volunteers, mean Cmax and AUC(0-10 h) of cabergoline increased to a similar degree during co-administration of clarithromycin."( Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.
Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nishikawa, N; Nomoto, M; Nomura, T; Yabe, H, 2006
)
0.83
"This review describes the pharmacologic and pharmacokinetic properties of selected DAs and relates these characteristics to clinical outcomes, with an emphasis on adverse events."( A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Burger, E; Härtter, S; Kvernmo, T, 2006
)
0.33
"05) reduction in assessed pharmacodynamic parameters was observed after intranasal administration of mucoadhesive microemulsion against control group."( Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.
Mishra, AK; Mishra, P; Misra, A; Sharma, G, 2009
)
0.74

Compound-Compound Interactions

This study investigated the efficacy and safety of high-dose Sandostatin® LAR® as monotherapy or in combination with pegvisomant or cabergoline in acromegalic patients with pituitary adenomas following previous failure of conventional SSA treatment.

ExcerptReferenceRelevance
" The method consists of liquid-liquid extraction after addition of deuterated internal standard, and reverse-phase liquid chromatography with electrospray ionization combined with tandem mass spectrometry (MS/MS)."( Quantitative determination of cabergoline in human plasma using liquid chromatography combined with tandem mass spectrometry.
Allievi, C; Dostert, P, 1998
)
0.59
"The efficacy of cabergoline solely or combined with a PGF2alpha analogue in inducing abortion at different stages of pregnancy was investigated in 18 queens."( Induction of abortion in queens by administration of cabergoline (Galastop) solely or in combination with the PGF2alpha analogue Alfaprostol (Gabbrostim).
Arbeiter, K; Aslan, S; Erünal-Maral, N; Findik, M; Handler, J; Yüksel, N, 2004
)
0.92
" The aim of this study was to evaluate the effectiveness of cabergoline (at doses of up 3 mg/week), alone or combined with relatively low doses of ketoconazole (up to 400 mg/day), in 12 patients with CD unsuccessfully treated by transsphenoidal surgery."( Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Agra, R; Albuquerque, JL; Arahata, CM; Arruda, MJ; Azevedo, MF; Canadas, V; Montenegro, L; Moura E Silva, L; Naves, LA; Pontes, L; Vilar, L, 2010
)
0.94
"The aim of this study was to compare the efficacy of antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins) combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who were at high risk for OHSS."( GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA, 2016
)
0.88
"Two hundred and thirty six patients were randomized in a 1:1 ratio to the cabergoline group or the antagonist rescue combined with cabergoline group."( GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA, 2016
)
0.92
"The incidence of moderate/severe OHSS was significantly lower in the antagonist rescue combined with cabergoline group [5."( GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA, 2016
)
0.91
"GnRH antagonist rescue protocol combined with cabergoline is more effective than cabergoline alone in the prevention of OHSS."( GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA, 2016
)
0.95
"Remission of acromegaly after treatment withdrawal seems to be uncommon in patients controlled by cabergoline, either as monotherapy or in combination with octreotide."( Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study.
Abucham, J; Bronstein, MD; Casagrande, A; Jallad, RS; Mota, JI; Tabet, A, 2017
)
0.9
"The aim of this work was to investigate the value of laparoscopic ovarian drilling (LOD) compared with GnRH antagonist flexible protocol combined with cabergoline (Cb), as a prophylaxis against the re-development of ovarian hyperstimulation syndrome (OHSS) in women with clomiphene citrate-resistant polycystic ovary disease (CCR-PCOD) who had severe OHSS before in a previous ICSI cycle."( Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Hefzy, E; Seyam, E, 2018
)
0.92
" This study investigated the efficacy and safety of high-dose Sandostatin® LAR® as monotherapy or in combination with pegvisomant or cabergoline in acromegalic patients with pituitary adenomas following previous failure of conventional SSA treatment."( Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W, 2019
)
0.93
"After three months of high-dose Sandostatin® LAR® monotherapy (40 mg), patients who achieved biochemical control (n = 7) continued to receive the same treatment for an additional four months, whereas uncontrolled patients were randomised to receive high-dose Sandostatin® LAR® in combination with pegvisomant (n = 31) or cabergoline (n = 32)."( Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W, 2019
)
0.9
"These data demonstrate that high-dose Sandostatin® LAR® as monotherapy or in combination with pegvisomant or cabergoline is a feasible salvage option in patients with pituitary adenomas not adequately controlled on conventional SSA regimens."( Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W, 2019
)
0.93
"This study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing's disease (CD)."( Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Bex, M; Biller, BMK; Boguszewski, CL; Chattopadhyay, A; Feelders, RA; Fleseriu, M; González-Devia, D; Kadioglu, P; Maamari, R; Patino, H; Pedroncelli, AM; Pivonello, R; Yavuz, DG, 2023
)
1.33

Bioavailability

The absolute bioavailability of cabergoline is unknown. The effect of formulation on the urinary pharmacokinetics, pharmacodynamics, and relative bioavailability was investigated.

ExcerptReferenceRelevance
"The effect of formulation on the urinary pharmacokinetics, pharmacodynamics, and relative bioavailability of cabergoline was investigated."( Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
Bizollon, CA; Edwards, DM; Persiani, S; Pianezzola, E; Piscitelli, G; Poggesi, I; Sassolas, G; Strolin Benedetti, M, 1994
)
0.76
" The absolute bioavailability of cabergoline is unknown."( Clinical pharmacokinetics of cabergoline.
Bonuccelli, U; Del Dotto, P, 2003
)
0.89
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cabergoline appears not to be associated with an increased risk of fibrotic adverse events. For 6 months following the second MRI study, the rat continued to receive the same dosage of cabergoline and had no clinical signs of disease or unusual behavior.

ExcerptRelevanceReference
" Dose-response studies in nursing bitches, using puppy weight as an endpoint, revealed that a dose of 5 micrograms/kg/day orally (for 5 days) was the optimal dose with a minimum of side effects."( Effects on pseudopregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats.
Arbeiter, K; Ballabio, R; D'Ver, AS; Jöchle, W; Post, K, 1989
)
0.28
" The effect was of rapid onset and long duration; the maximum or nearly maximum decrease was observed within 3 h after dosing as well as up to 96 h (200 and 300 micrograms) and up to 168 h (400 and 600 micrograms)."( Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta- carbonyl)-urea-diphosphate (FCE 21336).
Cammelli, L; Dubini, A; Mangili, R; Pontiroli, AE; Viberti, GC, 1987
)
0.27
" An antitumor effect of CG has been confirmed at a lower dosage than that of BC."( Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.
Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T, 1995
)
0.69
" Diary card "off-time" was improved by 42%, whereas the levodopa dosage was reduced by 18%."( Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
Ahlskog, JE; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, MD; Wheeler, K; Wright, KF, 1994
)
0.51
" Dose-response effects were not significant."( Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
Brewer, MA; Hutton, JT; Morris, JL, 1993
)
0.52
" In a subsequent open-label dose-escalation phase, further improvement was documented as the dosage was gradually raised to 10 mg daily."( Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF, 1996
)
0.68
" Dosage was titrated to optimal, using up to 6 mg of CBG or 40 mg of BCR daily."( Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E, 1996
)
0.59
" In the first study (de novo patients), cabergoline was administered at increasing dosages until the maximum dosage of 2 mg/day once a day for 8 weeks; subsequently L-dopa (250 mg/day) was added."( Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M, 1997
)
0.81
" Both drugs are relatively well-tolerated, with the exception of dyskinesias that require reduction of the levodopa dosage and occasional diarrhea."( New pharmacotherapy for Parkinson's disease.
Alldredge, BK; Aminoff, MJ; Bainbridge, JL; Dowling, GA; Gottwald, MD, 1997
)
0.3
"5 mg/day) achieved a statistically significant decrease in levodopa dosage compared with placebo (18 vs 3%) and improved the Unified Parkinson's Disease Rating Scale scores for activities of daily living in a greater number of patients (23 vs 4%)."( Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden, CD, 1998
)
0.6
" Also, when given as adjunctive therapy with levodopa, they can allow the levodopa maintenance dosage to be reduced without loss of symptom control."( Clinical pharmacology of dopamine agonists.
Lam, YW, 2000
)
0.31
" Six vixens were dosed with CAB at each day PI and abortions, total post-partum litter loss and the combined effects of both were compared with a group of vixens that received a placebo and a control group of vixens that received no treatment."( Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy.
Brzozowski, M; Clark, M; Marks, CA; Zurek, H, 2002
)
0.54
"Recently, Stewart and Ruberg proposed the use of contrast tests for detecting dose-response relationships."( Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.
Bretz, F; Hothorn, LA, 2002
)
0.31
"To demonstrate clinical effectiveness with smallest cabergolina dosage in lactation inhibition."( [Cabergoline for inhibition of lactation].
Bravo-Topete, EG; Briones-Garduño, C; Cejudo-Alvarez, J; Mendoza-Hernández, F,
)
1.04
" However, bromocriptine requires multiple daily dosing and some patients are resistant or intolerant to this therapy."( Current treatment issues in female hyperprolactinaemia.
Crosignani, PG, 2006
)
0.33
" Quinagolide may improve patient compliance to treatment owing to its reduced side effect profile, simple and rapid titration over just 7 days, once-daily dosing regimen and easy to use starter pack (available in some countries)."( Quinagolide--a valuable treatment option for hyperprolactinaemia.
Barlier, A; Jaquet, P, 2006
)
0.33
" In this patient the cabergoline dosage was temporarily decreased with no effect on the CSF leakage."( Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas.
Grotenhuis, JA; Hermus, AR; Netea-Maier, RT; Schakenraad, EL; Timmers, H; van Lindert, EJ, 2006
)
0.89
" Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased."( Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
Ballarino, C; Becu-Villalobos, D; Cristina, C; Mallea-Gil, MS; Perez-Millan, MI; Stalldecker, G; Villafañe, AM, 2009
)
0.83
"To define resistance to cabergoline (CAB) on the basis of a dose-response relationship established in a large series of macroprolactinoma patients and to assess the influence of gender and tumor invasiveness on the response to treatment."( Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
Abs, R; Daems, T; Delgrange, E; Maiter, D; Verhelst, J, 2009
)
0.9
"Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events."( Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM, 2010
)
2.03
"The goal of this study was to compare three different medications for the induction of abortion in bitches between day 22 and 40 after mismating, to reduce the dosage and frequency of PGF2alpha applications and to investigate the effects of additional intravaginal applications of misoprostol, a PGE1 analog."( Intravaginal application of misoprostol improves pregnancy termination with cabergoline and alfaprostol in dogs.
Aslan, S; Beceriklisoy, HB; Cetin, Y; Macun, HC; Schäfer-Somi, S,
)
0.36
" In 20 patients with uncured Cushing disease, treatment was initiated with cabergoline at a dosage of 1 mg/wk, with a monthly increment of 1 mg, until midnight serum cortisol (MNSC) or low-dose dexamethasone suppression serum cortisol (LDSC) (or both) normalized or a maximal dosage of 5 mg/wk was reached."( Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy.
Acharya, SV; Bandgar, T; George, J; Gopal, RA; Lila, AR; Menon, PS; Sarathi, V; Shah, NS,
)
0.74
"This study aimed to determine the effectiveness of short-term maintenance treatment with cabergoline and to find out minimum effective dosage of cabergoline during maintenance treatment for patients with microadenoma-related and idiopathic hyperprolactinemia."( Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Balcik, O; Buyukbayrak, EE; Karageyim Karsidag, AY; Kars, B; Pirimoglu, M; Turan, C; Unal, O, 2010
)
0.83
" Cabergoline was discontinued and oral bromocriptine was initiated at a dosage of 10 mg daily."( Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer, P; Molitch, ME,
)
1.28
" Pergolide was withdrawn from the US market in 2007 because of the risk of valvular heart disease, while the European Medicines Agency (EMA) required a reduction in the maximum daily dosage of cabergoline and pergolide from 6 mg/day to 3 mg/day in 2008."( The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Kubota, K; Ooba, N; Yamaguchi, T, 2011
)
0.56
" For 6 months following the second MRI study, the rat continued to receive the same dosage of cabergoline and had no clinical signs of disease or unusual behavior."( Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat.
DeCubellis, J; Donnelly, T; Kiupel, M; Mayer, J; Sato, A, 2011
)
0.92
" The dosage of DAs administered were rarely evaluated."( Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Bilge, A; Kurtulmus, N; Yarman, S, 2012
)
0.68
"To compare the efficacy and safety of two different dosing schedules of cabergoline in patients with macroprolactinoma."( A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Bhadada, SK; Bhansali, A; Dutta, P; Gupta, V; Rastogi, A; Sachdeva, N; Singh, P; Vijaivergiya, R; Walia, R, 2013
)
0.88
" A further increase in cabergoline dosage after normalization of prolactin in patients with tumour reduction of <50%, led to further tumour shrinkage by 31·2% in an additional 26·3% of patients."( A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Bhadada, SK; Bhansali, A; Dutta, P; Gupta, V; Rastogi, A; Sachdeva, N; Singh, P; Vijaivergiya, R; Walia, R, 2013
)
0.96
"Intensive treatment with cabergoline is not superior to the conventional recommended dosage schedule in respect to the time necessary to achieve normoprolactinemia and ≥50% tumour shrinkage."( A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma.
Bhadada, SK; Bhansali, A; Dutta, P; Gupta, V; Rastogi, A; Sachdeva, N; Singh, P; Vijaivergiya, R; Walia, R, 2013
)
0.95
" With sufficient dosage it is possible to normalize hormonal activity of acromegly in 95 % of patients."( [Contemporary options and perspectives in the treatment of acromegaly].
Marek, J, 2014
)
0.4
" Cabergoline was started at a standard weekly dosage and incrementally adjusted on individual posttreatment PRL values."( Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Fujii, S; Kambe, A; Kurosaki, M; Ogawa, T; Watanabe, T, 2015
)
1.59
" However, DNA isolated from the pituitary tissue and forearm skin showed duplicated dosage of GPR101, suggesting that he is mosaic for this genetic abnormality."( Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
Albrecht, S; Barry, S; Bunce, B; Caswell, R; Ellard, S; Evanson, J; Iacovazzo, D; Jose, S; Korbonits, M; Millette, M; Rodd, C; Roncaroli, F; Sampson, J; Stiles, CE; Trouillas, J, 2016
)
0.43
" SRL-pegvisomant combination normalized IGF-1 in the majority of patients; continued efficacy despite individual drug dosing reduction was also reported."( The role of combination medical therapy in the treatment of acromegaly.
Fleseriu, M; Lim, DS, 2017
)
0.46
" The MTT test was conducted to identify oxidative and reductive enzymes and to specify appropriate dosage at four concentrations of dopamine and Cabergoline on MCF-7 and SKBR-3 cells."( The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Ahangari, G; Bakhtou, H; Deezagi, A; Olfatbakhsh, A, 2019
)
0.71
" Dose-response studies in 2D and 3D human pancreatic NET cell cultures (BON-1 and QGP-1) were performed under serum-containing and serum-deprived conditions."( Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Culler, MD; de Herder, WW; Dogan-Oruc, F; Feelders, RA; Herrera-Martínez, AD; Hofland, LJ; Luque, RM; van den Dungen, R; van Koetsveld, PM, 2019
)
0.51
" is a potent, synthetic somatostatin analogue (SSA) that requires less frequent dosing and offers quality of life (QoL) benefits in acromegaly patients compared to its shorter-acting predecessor."( Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W, 2019
)
0.72
" The demographic data, dosage and duration of cabergoline, and serum prolactin levels at different time points were collected for analysis."( Treatment of hyperprolactinemia: A single-institute experience.
Chen, TY; Cheng, WY; Chien, Y; Huang, YF; Lai, CM; Lee, CH; Shen, CC; Yang, MY; Yang, YP, 2021
)
0.88
"This systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce patient burden and costs compared with standard dosing, while maintaining effectiveness."( A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly.
Fleseriu, M; Gadelha, M; Hanman, K; Haria, K; Houchard, A; Khawaja, S; Ribeiro-Oliveira, A; Zhang, Z, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
dopamine agonistA drug that binds to and activates dopamine receptors.
antiparkinson drugA drug used in the treatment of Parkinson's disease.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
N-acylureaA member of the class of ureas that has the general formula R-CO-NH-CO-NH2 or R-CO-NH-CO-NH-CO-R', formally derived by the acylation of one or both of the nitrogens of a urea moiety.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency26.02400.002541.796015,848.9004AID1347395; AID1347398
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.47710.01237.983543.2770AID1346984; AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency22.84910.005428.02631,258.9301AID1346982; AID1346985
cytochrome P450 2D6Homo sapiens (human)Potency1.54870.00108.379861.1304AID1645840
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1259385
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.91640.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency2.98490.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency19.95260.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.00140.00030.769310.0000AID725680
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Histamine H3 receptorHomo sapiens (human)Ki0.00140.00010.33998.5110AID725680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2BHomo sapiens (human)EC50 (µMol)0.01300.00040.20611.0000AID725679
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (203)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (65)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID725680Displacement of [125I](+/-)DOI from human 5-HT2B receptor transfected in CHO cell membrane after 60 mins by scintillation counting analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID725679Agonist activity at human 5-HT2B receptor transfected in CHO cell assessed as IP1 production incubated for 30 mins measured by HTRF detection method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345833Human D3 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345788Human D2 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345814Human D4 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345718Human D1 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345879Human D5 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345908Human alpha1A-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,173)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (1.28)18.7374
1990's138 (11.76)18.2507
2000's408 (34.78)29.6817
2010's460 (39.22)24.3611
2020's152 (12.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 105.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index105.82 (24.57)
Research Supply Index7.28 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index193.98 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (105.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials196 (15.57%)5.53%
Reviews185 (14.69%)6.00%
Case Studies311 (24.70%)4.05%
Observational10 (0.79%)0.25%
Other557 (44.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (56)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. [NCT01143584]20 participants (Anticipated)Interventional2010-05-31Recruiting
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial [NCT06029673]Phase 272 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Comparison of Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention:Randomized Controlled Trial [NCT03473613]Phase 3230 participants (Actual)Interventional2014-10-01Completed
Effect of Cabergoline on Subendometrial Vascularity During ICSI Cycles and Pregnancy Outcome [NCT02306564]Phase 2/Phase 3150 participants (Anticipated)Interventional2014-12-31Recruiting
The Effect Of Cabergoline On Follicular Microenvironment Profile In Patients With High Risk Of Ohss [NCT01569256]40 participants (Actual)Interventional2008-03-31Completed
Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility: Randomized Controlled Trial [NCT03549741]Phase 2/Phase 3120 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS [NCT05981742]Phase 275 participants (Actual)Interventional2022-09-21Completed
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial [NCT02288962]Phase 360 participants (Anticipated)Interventional2014-11-30Recruiting
Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women [NCT03928288]Phase 2140 participants (Anticipated)Interventional2019-12-02Recruiting
The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection . [NCT02620605]Phase 375 participants (Anticipated)Interventional2017-12-20Recruiting
Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: a Randomized Controlled Trial [NCT02461875]Phase 2236 participants (Anticipated)Interventional2013-05-31Recruiting
Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome [NCT02134249]Phase 2/Phase 3200 participants (Actual)Interventional2014-04-30Completed
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor [NCT00889525]Phase 30 participants Interventional2007-11-30Completed
Clinical Guidance to Increase Women's Awareness of Some Contributing Factors to Help Proper Treatment of Unexplained Resistant Hyperprolactinemia Not Responding to Therapeutic Dopamine Agonists (DA) [NCT04262024]Phase 1120 participants (Actual)Interventional2020-02-01Completed
Randomized, 4-Way Replicate Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fasting Conditions [NCT00653055]Phase 140 participants (Actual)Interventional2001-08-31Completed
Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility [NCT02644304]Phase 288 participants (Anticipated)Interventional2015-05-31Recruiting
Satisfaction of Patients With the Chosen Method of Inhibition of Lactation: With the Use of Drugs Lowering the Level of Prolactin or Without the Use of Pharmacological Agents in Postnatal Period, Taking Into Account Individual Conditions [NCT04038749]90 participants (Anticipated)Interventional2019-06-16Recruiting
The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction [NCT01065376]Phase 4120 participants (Anticipated)Interventional2010-01-31Completed
Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly [NCT01014793]19 participants (Actual)Observational2005-05-31Completed
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment [NCT00699530]0 participants (Actual)Observational2008-05-31Withdrawn
Randomized, 2-Way Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fed Conditions [NCT00652873]Phase 124 participants (Actual)Interventional2001-07-31Completed
Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults [NCT01395602]Phase 1/Phase 240 participants (Actual)Interventional2002-04-30Completed
Cabergoline Before or After Oocyte Collection for Follicular Resolution [NCT04096027]Phase 470 participants (Actual)Interventional2019-09-23Completed
[NCT01957839]Phase 448 participants (Actual)Interventional2010-03-31Completed
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stab [NCT00605683]Phase 3679 participants (Actual)Interventional2007-11-30Completed
Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome. A Randomized Controlled Trial [NCT02875587]Phase 2170 participants (Actual)Interventional2016-10-31Completed
Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome [NCT02271360]Phase 2/Phase 3200 participants (Actual)Interventional2014-04-30Completed
The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment [NCT00595140]Phase 410 participants (Actual)Interventional2008-01-31Completed
Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program [NCT01009567]Phase 1/Phase 210 participants (Anticipated)Interventional2009-06-30Completed
A Double-Blind, Randomized, Active-Controlled Multicenter Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) [NCT00625547]Phase 3361 participants (Actual)Interventional2003-01-31Completed
Cabergoline as a Preventive Treatment for Chronic Migraine: an Investigator-Initiated, Randomized Clinical Trial [NCT05525611]32 participants (Anticipated)Interventional2022-09-05Recruiting
A Double-blind, Randomized, Placebo-controlled Multicenter Efficacy Study for the Treatment of Patients With Restless Legs Syndrome (RLS) [NCT00627003]Phase 343 participants (Actual)Interventional2002-11-30Completed
A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients. [NCT00174239]Phase 4220 participants Interventional2004-07-31Terminated(stopped due to See Detailed Description for termination reason.)
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial [NCT03457389]68 participants (Anticipated)Interventional2018-02-22Recruiting
An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventio [NCT01278342]Phase 470 participants (Actual)Interventional2006-09-30Completed
Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's Disease [NCT00153972]Phase 439 participants (Actual)Interventional2005-02-28Completed
Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial [NCT03271918]Phase 3140 participants (Actual)Interventional2015-02-01Completed
Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction. [NCT00440258]Phase 360 participants Interventional2004-04-30Completed
Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline [NCT00460616]50 participants (Actual)Observational2007-01-31Completed
Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch [NCT01530490]Early Phase 180 participants (Actual)Interventional2007-08-31Completed
A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS. [NCT01535859]Phase 346 participants (Actual)Interventional2012-04-30Completed
A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease [NCT00129181]30 participants (Actual)Interventional2005-01-31Completed
Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence [NCT00033111]Phase 2140 participants (Actual)Interventional2001-06-30Completed
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study [NCT02542410]Phase 210 participants (Actual)Interventional2016-05-31Completed
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence [NCT01651364]Phase 111 participants (Actual)Interventional2011-07-31Completed
Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics [NCT01459601]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist [NCT01620138]Phase 2/Phase 321 participants (Actual)Interventional2010-03-31Completed
A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy [NCT00376064]Phase 420 participants (Actual)Interventional2006-03-31Completed
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients [NCT03313661]Phase 360 participants (Anticipated)Interventional2017-10-14Recruiting
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss [NCT04701333]Phase 273 participants (Actual)Interventional2021-04-01Completed
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment [NCT01794793]Phase 4413 participants (Actual)Interventional2013-06-10Active, not recruiting
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial [NCT06123026]Phase 4200 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline- Randomized Controlled Trial [NCT05024422]89 participants (Actual)Interventional2021-12-31Completed
A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease [NCT01915303]Phase 268 participants (Actual)Interventional2014-03-06Terminated
A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer [NCT01730729]Early Phase 120 participants (Actual)Interventional2013-02-11Completed
Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET Using Microdose GnRH Agonist Flare-Up-Protocol [NCT03263299]Phase 4120 participants (Anticipated)Interventional2017-08-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01278342 (3) [back to overview]The Percentage of Participants With Complete Response (CR) At 3 Months
NCT01278342 (3) [back to overview]The Percentage of Participants With Complete Response (CR) at 8 Months
NCT01278342 (3) [back to overview]The Percentage of Participants With Partial Response (PR) at 8 Months
NCT01620138 (1) [back to overview]Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma
NCT01730729 (8) [back to overview]Treatment Toxicity
NCT01730729 (8) [back to overview]Clinical Benefit Rate (CBR) After 2 Cycles of Treatment
NCT01730729 (8) [back to overview]Disease Control at 12 Months
NCT01730729 (8) [back to overview]Overall Response Rate (ORR) at 2 Months
NCT01730729 (8) [back to overview]Overall Survival (OS)
NCT01730729 (8) [back to overview]Progression Free Survival (PFS)
NCT01730729 (8) [back to overview]Change in Serum Prolactin Levels From Baseline and After 2 Cycles of Treatment
NCT01730729 (8) [back to overview]Correlate Tissue Prolactin Biomarkers With Response to Therapy
NCT01915303 (22) [back to overview]Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN Collected or Imputed at Week 35
NCT01915303 (22) [back to overview]Body Mass Index at Week 35
NCT01915303 (22) [back to overview]Body Weight at Week 35
NCT01915303 (22) [back to overview]Duration (Weeks) of Controlled or Partially Controlled Response
NCT01915303 (22) [back to overview]LDL, HDL and Total Cholesterol at Week 35
NCT01915303 (22) [back to overview]Mean Scores of Cushing QoL Standardized Score at Week 17 and 35
NCT01915303 (22) [back to overview]Mean Scores of SF-12v2 Domain Scores at Week 17 and 35
NCT01915303 (22) [back to overview]Mean Urinary Free Cortisol (mUFC) at Scheduled Visits
NCT01915303 (22) [back to overview]Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Dorsal Fat Pad
NCT01915303 (22) [back to overview]Plasma Adrenocorticotropic Hormone (ACTH)
NCT01915303 (22) [back to overview]Serum Cortisol Levels
NCT01915303 (22) [back to overview]Sitting Diastolic Blood Pressure at Week 35
NCT01915303 (22) [back to overview]Sitting Systolic Blood Pressure at Week 35
NCT01915303 (22) [back to overview]Waist Circumference at Week 35
NCT01915303 (22) [back to overview]Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Hirsutism
NCT01915303 (22) [back to overview]Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Striae
NCT01915303 (22) [back to overview]Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Supraclavicular Fat Pad
NCT01915303 (22) [back to overview]Number of Participants With Shift From Mild to Severe in Clinical Signs of Hypercortisolism
NCT01915303 (22) [back to overview]Number of Patients With Shift From Standing Easily to Not Being Able to Stand
NCT01915303 (22) [back to overview]Percentage of Participants Who Attain mUFC ≤ 1.0 x ULN or Have at Least 50% Reduction From Baseline in mUFC
NCT01915303 (22) [back to overview]Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN
NCT01915303 (22) [back to overview]Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Facial Rubor
NCT02542410 (2) [back to overview]Change in Score in Worst Pain Over the Last Month
NCT02542410 (2) [back to overview]Changes in Pain Interference Scores
NCT04701333 (5) [back to overview]Number of Participants Reporting Breast Pain
NCT04701333 (5) [back to overview]Number of Participants Reporting Significant Bother From Breast Pain
NCT04701333 (5) [back to overview]Number of Participants Reporting Significant Bother From Side-effects
NCT04701333 (5) [back to overview]Serum Prolactin Level
NCT04701333 (5) [back to overview]Number of Participants Experiencing Side-effects

The Percentage of Participants With Complete Response (CR) At 3 Months

"A patient was classified as CR if both biochemical parameters were controlled at the end of 3 months of treatment:~Mean 1 hour GH < 2.5µg/L (according to Central Laboratory); and~IGF-I within the Central Laboratory Normal Range (for age and gender)" (NCT01278342)
Timeframe: From Baseline to 3 months

Interventionpercent (Number)
Sandostatin LAR High Dose Alone60
Sandostatin LAR High Dose + Pegvisomat0
Sandostatin LAR High Dose + Cabergoline0

[back to top]

The Percentage of Participants With Complete Response (CR) at 8 Months

"A patient was classified as a Complete Responder (CR) if both biochemical parameters were controlled at the end of 8 months of treatment:~Mean 1 hour GH < 2.5µg/L (according to Central Laboratory); and~IGF-I within the Central Laboratory Normal Range (for age and gender)." (NCT01278342)
Timeframe: From Baseline to 8 months

Interventionpercent (Number)
Sandostatin LAR High Dose Alone25
Sandostatin LAR High Dose + Pegvisomat0
Sandostatin LAR High Dose + Cabergoline9.4

[back to top]

The Percentage of Participants With Partial Response (PR) at 8 Months

"Patients who met one of the following criteria at the end of 8 months of treatment were defined as Partial Responders, regardless of the treatment.~Mean 1 hour GH > 2.5 µg/L and < 5 µg/L and either a decrease in IGF-I of at least 50% compared to baseline or IGF-I within normal range.~Mean 1 hour GH < 2.5 µg/L and a decrease in IGF-I of at least 50% compared to baseline and IGF-I outside normal range." (NCT01278342)
Timeframe: From Baseline to 8 months

Interventionpercent (Number)
Sandostatin LAR High Dose Alone25
Sandostatin LAR High Dose + Pegvisomat22.6
Sandostatin LAR High Dose + Cabergoline21.9

[back to top]

Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma

Magnetic resonance imaging (MRI) of the sella and prolactin will be performed before (baseline) and after 6 months of treatment with cabergoline or pasireotide. Disease progression will be defined as tumor growth > 25%, stable disease as changes < 25% and significant tumor shrinkage as > 25% in tumor volume compared to baseline MRI (baseline to six months). (NCT01620138)
Timeframe: Baseline to six months

Interventioncmˆ3 (Median)
Pasireotide3.8
Cabergoline29.35

[back to top]

Treatment Toxicity

"Toxicity will be assessed at the beginning of each cycle (1 cycle equals 28 days) during treatment and 30 days post last treatment during treatment. Toxicity will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following:~Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE Grades 1 through 4 adverse events that were determined to be at least possibly related to treatment are combined and reported below." (NCT01730729)
Timeframe: After every 4 weeks (1 cycle) during treatment for up to 20 cycles and 30 days post last treatment

Interventionparticipants (Number)
NauseaFatigueHyponatremiaAlkaline Phosphatase increasedAspartate Aminotansferase increasedHyperglycemiaHypokalemiaVomitingPain in extremityAcute Kidney InjuryAlanine Aminotranserase increasedArthralgiaCreatinine increasedDiarrheaDizzinessDry eyeHyperkalemiaHypernatremiaHypocalcemiaHypoglycemiaInsomniaPainWhite Blood Cell decreased
Treatment (Cabergoline)65332221111111111111111

[back to top]

Clinical Benefit Rate (CBR) After 2 Cycles of Treatment

"Clinical Benefit Rate (CBR) is defined as the number of patients with Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and is assessed by RECIST guidelines for measurements of CT scan at 8 weeks (2 cycles) of treatment.~Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.~Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started" (NCT01730729)
Timeframe: After 8 weeks (2 cycles) of treatment

InterventionParticipants (Count of Participants)
Treatment (Cabergoline)6

[back to top]

Disease Control at 12 Months

Number of patients without progressive disease as assessed by CT scan and RECIST guidelines at 12 months of treatment. (NCT01730729)
Timeframe: At 12 months from start of treatment

InterventionParticipants (Count of Participants)
Treatment (Cabergoline)2

[back to top]

Overall Response Rate (ORR) at 2 Months

"Overall Response Rate (ORR) is defined as the number of patients that achieved Complete Response (CR) or Partial Response (PR) and will be assessed after 8 weeks (2 cycles) of therapy using CT scan images and RECIST guidelines.~Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.~Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started" (NCT01730729)
Timeframe: After 8 weeks (2 cycles) of treament

InterventionParticipants (Count of Participants)
Treatment (Cabergoline)0

[back to top]

Overall Survival (OS)

Overall Survival (OS) is defined from the first day of treatment until death from any cause. (NCT01730729)
Timeframe: From the start of treatment until death from any cause. Median follow up time of 6.817 months (95%CI 0.22-26.18)

InterventionMonths (Median)
Treatment (Cabergoline)10.41

[back to top]

Progression Free Survival (PFS)

Progression Free Survival (PFS) will be measured from time of treatment initiation until first documentation of progression of disease or death from any cause. (NCT01730729)
Timeframe: From start of treatment until progression of disease or death

InterventionMonths (Median)
Treatment (Cabergoline)1.84

[back to top]

Change in Serum Prolactin Levels From Baseline and After 2 Cycles of Treatment

Serum prolactin measurements were taken at baseline and after completion of two cycles of treatment. The mean drop was calculated for all patients, and for patients with best response of Stable Disease and Progressive Disease. (NCT01730729)
Timeframe: At baseline and after 2 cycles of treatment where 1 cycle =4 weeks

Interventionng/ml (Mean)
AllStable DiseaseProgressive Disease
Treatment (Cabergoline)-9.425-8.72-9.93

[back to top]

Correlate Tissue Prolactin Biomarkers With Response to Therapy

Baseline tumor tissue was analyzed for prolactin receptor (PRLr) expression and was provided with an IHC-based Allred score of 0 to 300 based on percentage intensity where lower scores indicate less PRLr expression and high scores indicate more PRLr expression. Only the malignant epithelium was scored. The score was correlated with best response of patient. (NCT01730729)
Timeframe: At baseline

Interventionscore on a scale (Median)
Stable DiseaseProgressive Disease
Treatment (Cabergoline)170220

[back to top]

Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN Collected or Imputed at Week 35

Participants who attained mUFC ≤ 1.0 x ULN (upper limit of normal) with pasireotide alone or in combination with cabergoline. The 24h-UFC concentration results from three samples, collected during the screening period, were averaged to obtain the Baseline urinary free cortisol level. mean 24h-UFC was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit. Imputation: subjects who completed the end of treatment visit at Week 35, but had missing evaluation of mean urinary free cortisol (mUFC). The last available mUFC assessment at or after previous visit (week) before last week was carried forward as the last week mUFC assessment. (NCT01915303)
Timeframe: Baseline up to week 35

Interventionpercentage of responders (Number)
All Patients50.0

[back to top]

Body Mass Index at Week 35

Body mass index was one of the measurements of clinical symptoms of CD. Body mass index=weight in kg divided by the square of the body height (in meters) (NCT01915303)
Timeframe: Baseline and week 35

Interventionkg/m2 (Mean)
BaselineWeek 35 n=41
All Patients31.328.4

[back to top]

Body Weight at Week 35

Weight was was one of the measures of clinical symptoms of CD (NCT01915303)
Timeframe: Baseline and week 35

Interventionkg (Mean)
BaselineWeek 35 n=41
All Patients82.275.6

[back to top]

Duration (Weeks) of Controlled or Partially Controlled Response

Duration of controlled or partially controlled response is defined as the period starting from the date of patient's first normalization (mUFC ≤ 1.0 x ULN) or at least 50% reduction from baseline up to the date when the patient's mUFC > 1.0 x ULN and the reduction from baseline falls to less than 50% from the first time (NCT01915303)
Timeframe: from the date patient's first normalization (mUFC ≤ 1.0xULN) or at least 50% reduction from baseline up to the date when the patient's mUFC > 1.0 x ULN

Interventionweeks (Median)
Core n=36Extension n=20
All Patients13.122.0

[back to top]

LDL, HDL and Total Cholesterol at Week 35

LDL=Low density lipoprotein, HDL=high density llipoprotein and total protein were analyzed by a central laboratory (NCT01915303)
Timeframe: Baseline and week 35

Interventionmmol/L (Mean)
HDL BaselineHDL Week 35 n=41LDL BaselineLDL Week 35 n=41Total BaselineTotal Week 35 n=41
All Patients1.51.53.22.869.468.6

[back to top]

Mean Scores of Cushing QoL Standardized Score at Week 17 and 35

Patients who completed nine or more items for the 12-item Cushing's syndrome QoL questionaire were considered evaluable for that assessment. Raw scores were obtained for the 12 items using the following scoring: 1) always or very much, 2) often or quite a bit, 3) sometimes or somewhat, 4) rarely or very little, 5) never or not at all. Then the standardized score, Y, was calculated for each patient as follows: Y = 100* (X - n) / n*5 - n*1) = 100 * (X - n) / 4*n where X denoted the raw score and n the number of questions answered by the patient. The higher the score, the better the QoL. The best possible standardized score was 100 and the worst possible standardized score was 0 (NCT01915303)
Timeframe: Baseline and week 17 and 35

Interventionscores on a scale (Mean)
Baseline MeanWeek 17 n=54Week 35 n=40
All Patients41.646.347.6

[back to top]

Mean Scores of SF-12v2 Domain Scores at Week 17 and 35

SF-12v2 General Health Survey is a general patient reported outcome instrument over time. It is scored to provide eight health domain scores (Bodily Pain (BP), General Health (GH), Physical Functioning (PF), Role-Physical (RP), Social Functioning (SF), Role-Emotional (RE), Vitality (VT) and Mental Health (MH)). These eight domain scores can be combined to form two summary scores reflecting overall physical and mental health: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The analyses reported here focus on PCS and MCS scores. The domain scores use a norm-based score, which standardizes the scores with respect to the mean and standard deviation of a nationally representative sample of United States (US) adults. These are the scores on the original scale which have not been transformed in any way. The possible range of scores is 0 to 100, with higher scores representing better outcomes. (NCT01915303)
Timeframe: Baseline, week 17 and 35

Interventionscores on a scale (Mean)
Baseline Bodily pain scaleWeek 17 n=52 Bodily pain scaleWeek 35 n=40 Bodily pain scaleBaseline n=67 General health scale:Week 17 n=52 General health scale:Week 35 n=40 General health scale:Baseline n=67 Mental componentWeek 17 n=52 Mental componentWeek 35 n=40 Mental componentBaseline n=67 Mental healthWeek 17 n=52 Mental healthWeek 35 n=40 Mental healthBaseline n=67 Physical component summaryWeek 17 n=52 Physical component summaryWeek 35 n=40 Physical component summaryBaseline n=67 Physical functioningWeek 17 n=52 Physical functioningWeek 35 n=40 Physical functioningBaseline n=67 Role emotionalWeek 17 n=52 Role emotionalWeek 35 n=40 Role emotionalBaseline n=67 Role physical scale:Week 17 n=52 Role physical scale:Week 35 n=40 Role physical scale:Baseline n=67 Social functioningWeek 17 n=52 Social functioningWeek 35 n=40 Social functioningBaseline n=67 Vitality scale:Week 17 n=52 Vitality scale:Week 35 n=40 Vitality scale:
All Patients42.945.144.938.940.940.742.441.942.141.943.042.442.744.043.442.141.942.139.738.038.742.342.841.342.243.043.347.245.745.6

[back to top]

Mean Urinary Free Cortisol (mUFC) at Scheduled Visits

Mean value of mUFC at each scheduled visit was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit when UFC was measured. (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 8 weeks during extension

Interventionnmol/24h (Mean)
BaselineCore Week 2 n-8Core Week 4 n=59Core Week 8 n=58Core Week 13 n=51Core Week 17 n=57Core Week 22 n=50Core Week 26 n=54Core Week 31 n=46Core Week 35 n=45Ext Week 43 n=22Ext Week 51 n=20Ext Week 59 n=24Ext Week 67 n=17Ext Week 75 n=18Ext Week 83 n=20Ext Week 91 n=18Ext Week 99 n=13Ext Week 107 n=12Ext Week 115 n=13Ext Week 123 n=13Ext Week 131 n=11Ext Week 139 n=9Ext Week 147 n=9Ext Week 155 n=4Ext Week 163 n=6Ext Week 171 n=6Ext Week 179 n=4Ext Week 187 n=4Ext Week 195 n=3Ext Week 203 n=4Ext Week 211 n=3Ext Week 219 n=2Ext Week 227 n=2Ext Week 235 n=3Ext Week 243 n=1Ext Week 251 n=1Ext Week 267 n=1
All Patients501.6217.0242.1230.0231.0310.3214.0211.6154.3184.8136.1156.8157.7213.8157.6157.9180.0222.5118.5126.0147.576.492.990.176.3141.189.561.389.946.1194.0107.370.647.162.0117.7202.9249.0

[back to top]

Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Dorsal Fat Pad

Clinical symptoms include: facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad. Two photographs, one frontal and one lateral from the shoulders up were taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position were taken to assess striae, and hirsutism. The photographs were assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 16 weeks during extension

Interventionparticipants (Number)
Core Week 1 n=40Core Week 2 n-37Core Week 4 n=37Core Week 8 n=37Core Week 13 n=32Core Week 17 n=32Core Week 22 n=28Core Week 26 n=31Core Week 31 n=32Core Week 35 n=26Ext Week 43 n=11Ext Week 59 n=10Ext Week 75 n=12Ext Week 91 n=10Ext Week 107 n=9Ext Week 123 n=10Ext Week 139 n=7Ext Week 155 n=4Ext Week 171 n=3Ext Week 187 n=3Ext Week 203 n=4Ext Week 219 n=2Ext Week 235 n=3Ext Week 251 n=1Ext Week 267 n=1
All Patients645548812139345323311211200

[back to top]

Plasma Adrenocorticotropic Hormone (ACTH)

A pre-dose blood draw for plasma ACTH sampling was taken at visits. Samples were analyzed by a central laboratory. (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 8 weeks during extension

Interventionpmol/L (Mean)
BaselineCore Week 2 n-62Core Week 4 n=63Core Week 8 n=61Core Week 13 n=53Core Week 17 n=58Core Week 22 n=49Core Week 26 n=55Core Week 31 n=49Core Week 35 n=40Ext Week 43 n=23Ext Week 51 n=21Ext Week 59 n=23Ext Week 67 n=22Ext Week 75 n=22Ext Week 83 n=19Ext Week 91 n=19Ext Week 99 n=16Ext Week 107 n=13Ext Week 115 n=15Ext Week 123 n=14Ext Week 131 n=12Ext Week 139 n=10Ext Week 147 n=9Ext Week 155 n=9Ext Week 163 n=5Ext Week 171 n=5Ext Week 179 n=5Ext Week 187 n=5Ext Week 195 n=4Ext Week 203 n=4Ext Week 211 n=3Ext Week 219 n=2Ext Week 227 n=2Ext Week 235 n=3Ext Week 243 n=1Ext Week 251 n=1Ext Week 267 n=1
All Patients16.312.414.213.311.912.313.712.412.111.011.510.410.711.09.19.810.611.39.39.510.68.210.010.410.410.07.47.08.69.08.011.06.07.010.36.07.04.0

[back to top]

Serum Cortisol Levels

A pre-dose blood draw for an 8 am fasting serum cortisol measurement were taken at visits. Samples were analyzed by a central laboratory. (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 8 weeks during extension

Interventionnmol/L (Mean)
BaselineCore Week 2 n-62Core Week 4 n=64Core Week 8 n=61Core Week 13 n=53Core Week 17 n=58Core Week 22 n=49Core Week 26 n=55Core Week 31 n=49Core Week 35 n=40Ext Week 43 n=23Ext Week 51 n=21Ext Week 59 n=21Ext Week 67 n=22Ext Week 75 n=21Ext Week 83 n=19Ext Week 91 n=19Ext Week 99 n=16Ext Week 107 n=13Ext Week 115 n=15Ext Week 123 n=14Ext Week 131 n=12Ext Week 139 n=10Ext Week 147 n=10Ext Week 155 n=8Ext Week 163 n=6Ext Week 171 n=5Ext Week 179 n=5Ext Week 187 n=5Ext Week 195 n=4Ext Week 203 n=4Ext Week 211 n=3Ext Week 219 n=2Ext Week 227 n=2Ext Week 235 n=3Ext Week 243 n=1Ext Week 251 n=1Ext Week 267 n=1
All Patients738.6626.1663.6649.0628.8683.0625.4632.7597.5538.2525.5512.2547.5495.4458.5419.5501.2470.9463.4501.7441.6413.8404.0585.4472.5617.0648.6599.0609.8418.8514.0551.3482.0324.5384.7679.0574.0638.0

[back to top]

Sitting Diastolic Blood Pressure at Week 35

The mean arterial blood pressure determinations were obtained in the sitting position. Three measurements were taken with 5 minute intervals and the mean was used for study specific procedures (NCT01915303)
Timeframe: Baseline and week 35

InterventionmmHg (Mean)
BaselineWeek 35 n=41
All Patients81.877.2

[back to top]

Sitting Systolic Blood Pressure at Week 35

The mean arterial blood pressure determinations were obtained in the sitting position. Three measurements were taken with 5 minute intervals and the mean was used for study specific procedures (NCT01915303)
Timeframe: Baseline and week 35

InterventionmmHg (Mean)
BaselineWeek 35 n=41
All Patients125.9119.5

[back to top]

Waist Circumference at Week 35

Waist circumference was one of the measurements of clinical signs of CD (NCT01915303)
Timeframe: Baseline and week 35

Interventioncm (Mean)
BaselineWeek 35 n=41
All Patients104.199.1

[back to top]

Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Hirsutism

Clinical symptoms include: facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad. Two photographs, one frontal and one lateral from the shoulders up were taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position were taken to assess striae, and hirsutism. The photographs were assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 16 weeks during extension

Interventionparticipants (Number)
Core Week 1 n=35Core Week 2 n-33Core Week 4 n=32Core Week 8 n=32Core Week 13 n=27Core Week 17 n=28Core Week 22 n=25Core Week 26 n=27Core Week 31 n=28Core Week 35 n=23Ext Week 43 n=10Ext Week 59 n=9Ext Week 75 n=10Ext Week 91 n=9Ext Week 107 n=8Ext Week 123 n=9Ext Week 139 n=7Ext Week 155 n=4Ext Week 171 n=4Ext Week 187 n=3Ext Week 203 n=4Ext Week 219 n=2Ext Week 235 n=3Ext Week 251 n=1Ext Week 267 n=1
All Patients5344435897223212222221100

[back to top]

Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Striae

Clinical symptoms include: facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad. Two photographs, one frontal and one lateral from the shoulders up were taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position were taken to assess striae, and hirsutism. The photographs were assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 16 weeks during extension

Interventionparticipants (Number)
Core Week 1 n=40Core Week 2 n-37Core Week 4 n=38Core Week 8 n=37Core Week 13 n=32Core Week 17 n=32Core Week 22 n=28Core Week 26 n=31Core Week 31 n=32Core Week 35 n=26Ext Week 43 n11=Ext Week 59 n=11Ext Week 75 n=12Ext Week 91 n=10Ext Week 107 n=9Ext Week 123 n=10Ext Week 139 n=7Ext Week 155 n=4Ext Week 171 n=3Ext Week 187 n=3Ext Week 203 n=4Ext Week 219 n=2Ext Week 235 n=3Ext Week 251 n=1Ext Week 267 n=1
All Patients52587779128111100010010101

[back to top]

Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Supraclavicular Fat Pad

Clinical symptoms include: facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad. Two photographs, one frontal and one lateral from the shoulders up were taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position were taken to assess striae, and hirsutism. The photographs were assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 8 weeks during extension

Interventionparticipants (Number)
Core Week 1 n=40Core Week 2 n-37Core Week 4 n=37Core Week 8 n=37Core Week 13 n=32Core Week 17 n=32Core Week 22 n=28Core Week 26 n=31Core Week 31 n=32Core Week 35 n=26Ext Week 43 n=11Ext Week 59 n=11Ext Week 75 n=12Ext Week 91 n=10Ext Week 107 n=9Ext Week 123 n=10Ext Week 139 n=7Ext Week 155 n=4Ext Week 171 n=3Ext Week 187 n=3Ext Week 203 n=4Ext Week 219 n=2Ext Week 235 n=3Ext Week 251 n=1Ext Week 267 n=1
All Patients6768899101211101101111111200

[back to top]

Number of Participants With Shift From Mild to Severe in Clinical Signs of Hypercortisolism

Facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad were assessed. Two photographs, one frontal and one lateral from the shoulders up will be taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position will be taken to assess striae, and hirsutism. The photographs must be assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 1, 2, 4, every 4 or 5 weeks during core, every 8 weeks during extension

Interventionparticipants (Number)
Core Week 4 Facial rubor baseline n=17Core Week 35 Facial rubor baseline n=17Ext Week 43 Facial rubor baseline n=17Ext Week 59 Facial rubor baseline n=17Ext Week 67 Facial rubor baseline n=17Ext Week 83 Facial rubor baseline n=17Ext Week 91 Facial rubor baseline n=17Ext Week 99 Facial rubor baseline n=17Ext Week 107 Facial rubor baseline n=17Ext Week 115 Facial rubor baseline n=17Ext Week 123 Facial rubor baseline n=17Core Week 1 Hirsutism baseline n=12Core Week 2 Hirsutism baseline n=12Ext Week 59 Striae baseline n=10Ext Week 99 Striae baseline n=10Ext Week 107 Striae baseline n=10Ext Week 115 Striae baseline n=10Ext Week 123 Striae baseline n=10Ext Week 99 Supraclavicular fat pad BL n=17Ext Week 107 Supraclavicular fat pad BL n=17
All Patients11111111111111111111

[back to top]

Number of Patients With Shift From Standing Easily to Not Being Able to Stand

"To test proximal muscle strength patients should be placed in a low seated position (for instance on an examination room stool). They should be asked to extend the arms in front of them. From this seated position patients will be asked to stand up. Patients will be evaluated using the following scale: 3. - completely unable to stand 2. - able to stand only by using arms as assistance~1. - able to stand after several efforts without using arms as assistance 0. - able to stand easily with arms extended" (NCT01915303)
Timeframe: Baseline up to week 267

Interventionparticipants (Number)
Core Week 26Core Week 35
All Patients11

[back to top]

Percentage of Participants Who Attain mUFC ≤ 1.0 x ULN or Have at Least 50% Reduction From Baseline in mUFC

Actual mean value of mUFC at each scheduled visit was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit when UFC was measured. (NCT01915303)
Timeframe: Baseline up to week 235

Interventionpercentage of responders (Number)
BaselineCore Week 17 n=57Core Week 35 n=45Ext Week 43 n=22Ext Week 67 n=17Ext Week 91 n=18Ext Week 115 n=13Ext Week 139 n=9Ext Week 163 n=6Ext Week 187 n=4Ext Week 211 n=3Ext Week 235 n=3
All Patients4.454.468.986.476.583.392.377.883.310066.7100

[back to top]

Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN

Actual mean value of mUFC at each scheduled visit was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit when UFC was measured. (NCT01915303)
Timeframe: Baseline up to week 235

Interventionpercentage of responders (Number)
BaselineCore Week 17 n=57Core Week 35 n=45Ext Week 43 n=22Ext Week 67 n=17Ext Week 91 n=18Ext Week 115 n=13Ext Week 139 n=9Ext Week 163 n=6Ext Week 187 n=4Ext Week 211 n=3Ext Week 235 n=3
All Patients4.428.148.963.647.161.176.977.866.775.066.7100

[back to top]

Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Facial Rubor

Clinical symptoms include: facial rubor, hirsutism, striae, and supraclavicular and dorsal fat pad. Two photographs, one frontal and one lateral from the shoulders up were taken to assess facial plethora, supraclavicular and dorsal fat pads. Two photographs, frontal and dorsal of the trunk with patient in standing position were taken to assess striae, and hirsutism. The photographs were assessed by a qualified physician at the site. Improvement=decrease in severity of symptom since baseline (NCT01915303)
Timeframe: Baseline, weeks 2, 4, every 4 or 5 weeks during core, every 16 weeks during extension

Interventionparticipants (Number)
Core Week 1 n=40Core Week 2 n=37Core Week 4 n=38Core Week 8 n=37Core Week 13 n=32Core Week 17 n=32Core Week 22 n=28Core Week 26 n=31Core Week 31 n=32Core Week 35 n=26Ext Week 43 n=11Ext Week 59 n=11Ext Week 75 n=12Ext Week 91 n=10Ext Week 107 n=9Ext Week 123 n=10Ext Week 139 n=7Ext Week 155 n=4Ext Week 171 n=3Ext Week 187 n=3Ext Week 203 n=4Ext Week 219 n=2Ext Week 235 n=3Ext Week 251 n=1Ext Week 267 n=1
All Patients58812111110141513233332200000000

[back to top]

Change in Score in Worst Pain Over the Last Month

"visual analog scale, minimum=0 and maximum=10 Higher numbers are a worse outcome~Outcome measures is calculated as the value at 6 months minus value at baseline." (NCT02542410)
Timeframe: Baseline, 6 months

Interventionscore on a scale (Median)
Norethindrone Acetate 5 mg-0.5
Cabergoline 0.5 mg-5

[back to top]

Changes in Pain Interference Scores

"Brief Pain Inventory Interference subscale is a 7-item self-report measure, designed to assess the extent to which pain interferes with various components of functioning, including physical and emotional functioning and sleep.The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assess the extent to which pain interferes with sleep. The arithmetic mean of the seven interference items is used as a measure of pain interference (i.e., how much a participant's pain interferes with her ability to complete activities of daily living and functioning). The score on the pain interference subscale ranges from 0-70. Higher scores are worse outcomes.~Outcome measure calculated as the value at 6 months minus the value at baseline" (NCT02542410)
Timeframe: Baseline, 6 months

Interventionunits on a scale (Mean)
Norethindrone Acetate 5 mg0.85
Cabergoline 0.5 mg0

[back to top]

Number of Participants Reporting Breast Pain

Participants will assess their breast symptoms using the validated Bristol Breast Inventory survey to assess 4 domains of breast symptoms: tenderness, engorgement, leaking milk, pain relief. Participants who indicated symptoms in any of these areas met the criteria for this outcome. (NCT04701333)
Timeframe: Day 4 after procedure

InterventionParticipants (Count of Participants)
Cabergoline10
Placebo32

[back to top]

Number of Participants Reporting Significant Bother From Breast Pain

Assessed using a Facial Pain Score (scale range 0-6, significant bother >=4) (NCT04701333)
Timeframe: Day 4 after procedure

InterventionParticipants (Count of Participants)
Cabergoline1
Placebo11

[back to top]

Number of Participants Reporting Significant Bother From Side-effects

Assessed using a Facial Pain Score (scale range 0-6, significant bother >=4) (NCT04701333)
Timeframe: Day 4 after procedure

InterventionParticipants (Count of Participants)
Cabergoline2
Placebo6

[back to top]

Serum Prolactin Level

A subset of participants returned blood tests to measure effectiveness of drug (NCT04701333)
Timeframe: Day 4 after procedure

Interventionng/mL (Mean)
Cabergoline6.5
Placebo18.0

[back to top]

Number of Participants Experiencing Side-effects

Participants selected from previously documented side-effects from the dopaminergic class or free-text. Participants may have reported more than one side-effect. (NCT04701333)
Timeframe: 2 weeks

,
InterventionParticipants (Count of Participants)
Nausea/ vomitingHeadacheDizziness/ lightheadnessConstipationAcid refluxFatigueLower extremity edemaHot flashesPalpitationsAnxietyInsomniaVisual disturbance
Cabergoline512714312421481
Placebo297182114913112

[back to top]